Hooman Kamel

Feb 7, 2024 | healio.com | Scott Buzby |Richard Smith |Hooman Kamel |Gregory M Marcus

You've successfully added Cardiology: Stroke to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Apixaban did not reduce recurrent stroke risk in patients with atrial cardiopathy without AF. The ARCADIA trial was stopped early for futility.

Jan 1, 2024 | sciencedirect.com | Hooman Kamel

• None Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial • None Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures • None Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study • None Real-world safety and effectiveness of cenobamate in...

Nov 9, 2023 | sciencedirect.com | Hooman Kamel |Margreet Kloppenburg

• None Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials• None MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study• None Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group.

Oct 30, 2023 | jamanetwork.com | Richard Bernstein |Hooman Kamel |Christopher B Granger |Jonathan P. Piccini

Key PointsQuestion  Do insertable cardiac monitors (ICMs) detect more atrial fibrillation (AF) than usual care in patients with recent ischemic stroke attributed to large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD)? Findings  The STROKE AF trial randomized 492 patients with stroke attributed to LAD or SVD to ICM or usual care. AF rates at 3 years were 21.7% in the ICM group and 2.4% in the control group, a statistically significant difference.